Browsing by Author Novartis International AG

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 38  next >
Issue DateTitleAuthor(s)
22-Sep-2016Antimalarial activity of KAF156 in falciparum and vivax malariaNicholas J. White; Tran T. Duong; Chirapong Uthaisin; Fran'ois Nosten; Aung P. Phyo; Borimas Hanboonkunupakarn; Sasithon Pukrittayakamee; Podjanee Jittamala; Kittiphum Chuthasmit; Ming S. Cheung; Yiyan Feng; Ruobing Li; Baldur Magnusson; Marc Sultan; Daniela Wieser; Xiaolei Xun; Rong Zhao; Thierry T. Diagana; Peter Pertel; F. Joel Leong; Mahidol-Oxford Tropical Medicine Research Unit; Department of Clinical Tropical Medicine; Mahidol University; Phusing Hospital; Mae Ramat District Hospital; Nuffield Department of Clinical Medicine; National Institute of Malaria, Parasitology and Entomology; Novartis International AG; Novartis Institutes for BioMedical Research; Novartis Institutes for Biomedical Research; Novartis Institute for Tropical Diseases Pte. Ltd.; Novartis Institutes for BioMedical Research, Inc.
1-Jan-2000Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malariaM. Van Vugt; S. Looareesuwan; P. Wilairatana; R. McGready; L. Villegas; I. Gathmann; R. Mull; A. Brockman; N. J. White; F. Nosten; Shoklo Malaria Research Unit; Academic Medical Centre, University of Amsterdam; Mahidol University; Ministry of Health; Novartis International AG; John Radcliffe Hospital
18-Sep-2015Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: A systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataElizabeth A. Ashley; Francesca Aweeka; Karen I. Barnes; Quique Bassat; Steffen Borrmann; Prabin Dahal; Timothy M.E. Davis; Mey Bouth Denis; Abdoulaye A. Djimde; Jean François Faucher; Blaise Genton; Philippe J. Guérin; Kamal Hamed; Eva Maria Hodel; Liusheng Huang; Vincent Jullien; Harin A. Karunajeewa; Jean René Kiechel; Poul Erik Kofoed; Gilbert Lefèvre; Niklas Lindegardh Lindegardh; Andreas Mårtensson; Mayfong Mayxay; Rose Mcgready; Clarissa Moreira; Paul N. Newton; Billy E. Ngasala; Francois Nosten; Christian Nsanzabana; Sunil Parikh; Patrice Piola; Ric N. Price; Pascal Ringwald; Lars Rombo; Birgit Schramm; Carol Hopkins Sibley; Kasia Stepniewska; Joel Tarning; Johan Ursing; Michele Van Vugt; Nicholas J. White; Lesley J. Workman; Philippe Deloron; Kevin Marsh; Shoklo Malaria Research Unit; Mahidol University; University of California, San Francisco; WorldWide Antimalarial Resistance Network (WWARN); University of Cape Town; Instituto de Salud Global de Barcelona; Centro de Investigação em Saúde de Manhiça (CISM); Wellcome Trust Research Laboratories Nairobi; Universitat Tubingen; Nuffield Department of Clinical Medicine; University of Western Australia; IRD Institut de Recherche pour le Developpement; Universite Paris Descartes; National Center for Parasitology; Organisation Mondiale de la Sante; University of Bamako Faculty of Medicine, Pharmacy and Odonto-Stomatology; Hopital Jean Minjoz; Swiss Tropical and Public Health Institute (Swiss TPH); Centre Hospitalier Universitaire Vaudois; Novartis Pharmaceuticals Corporation; Liverpool School of Tropical Medicine; Drugs for Neglected Diseases Initiative; Syddansk Universitet; Kolding Sygehus; Novartis International AG; Kenya Medical Research Institute; Karolinska Institutet; Wellcome Trust; Muhimbili University of Health and Allied Sciences; Yale Schools of Public Health and Medicine; Department of Clinical Pharmacology; Institut Pasteur de Madagascar; Menzies School of Health Research; Uppsala Universitet; Epicentre; University of Washington, Seattle; University of Amsterdam
1-Jan-2001A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in ThailandGilbert Lefèvre; Sornchai Looareesuwan; Sombat Treeprasertsuk; Srivicha Krudsood; Udomsak Silachamroon; Insa Gathmann; Robert Mull; Rajesh Bakshi; Novartis International AG; Mahidol University
1-Mar-2011Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: A subanalysis of the EPIC study of deferasiroxVip Viprakasit; Hishamshah Ibrahim; Shau Yin Ha; Phoebe Joy Ho; Chi Kong Li; Lee Lee Chan; Chang Fang Chiu; Pranee Sutcharitchan; Dany Habr; Gabor Domokos; Bernard Roubert; Hong Ling Xue; Donald K. Bowden; Kai Hsin Lin; Mahidol University; Kuala Lumpur Hospital; The University of Hong Kong; Royal Prince Alfred Hospital; Prince of Wales Hospital Hong Kong; University of Malaya Medical Centre; China Medical University Hospital Taichung; Chulalongkorn University; Novartis Pharmaceuticals Corporation; Novartis International AG; Novartis Asia Pacific Pharmaceuticals Pte Ltd; Monash Medical Centre; National Taiwan University Hospital
1-Jan-1999Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrineNicholas J. White; Michele Van Vugt; Farkad Ezzet; Mahidol University; Academic Medical Centre, University of Amsterdam; Nuffield Department of Clinical Medicine; Shoklo Malaria Research Unit; Novartis International AG
1-Jan-2011Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadDudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher; Royal Brompton Hospital; UCL; Universita degli Studi di Milano; University of Malaya Medical Centre; Cairo University; Ege University Medical School; Kuala Lumpur Hospital; Prince of Wales Hospital Hong Kong; Mahidol University; Ain Shams University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; American University of Beirut
1-Jun-2013Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Yiyun Zhang; M. Domenica Cappellini; American University of Beirut Medical Center; UCL Cancer Institute; Mahidol University; University of Athens; Chulalongkorn University; Ospedale Regional Microcitemie; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano
1-Nov-2013Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Zewen Zhu; M. Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; Chulalongkorn University; Universita degli Studi di Cagliari; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano
1-Jun-2012Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia majorDudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen S. Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher; Royal Brompton Hospital; UCL; Universita degli Studi di Milano; University of Malaya Medical Centre; Cairo University; Ege Universitesi; Kuala Lumpur Hospital; Prince of Wales Hospital Hong Kong; Mahidol University; Ain Shams University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; American University of Beirut
1-Sep-2010Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Arnold Ganser; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Gabor Domokos; Bernard Roubert; Christian Rose; L. Agaoglu; G. Alimena; D. Alonso; S. Ame; E. Angelucci; B. Arrizabalaga; M. Athanasiou-Metaxa; B. Augustson; Y. Aydinok; A. Baba; M. Baccarani; J. Beck; P. Beris; O. Beyne-Rauzy; H. Birgens; D. Bordessoule; C. Borgna-Pignatti; A. Bosly; K. Bouabdallah; D. Bowden; D. Bowen; D. Bron; M. D. Cappellini; M. Capra; G. Cartron; M. Cazzola; C. Chalkias; L. L. Chan; S. Chancharunee; C. Chapman; P. Charoenkwan; E. Chasapopoulou; S. Cheze; A. Chuansumrit; P. Cianciulli; C. Dauriac; M. Delforge; G. Dölken; H. Dombret; J. Duyster; T. Economopoulos; G. Ehninger; M. Elalfy; A. El-Beshlawy; L. Enggaard; G. Fillet; A. Filosa; G. Forni; R. Galanello; G. Gastl; S. Giraudier; A. Goldfarb; A. Grigg; F. Gumruk; S. Y. Ha; D. Haase; B. Heinrich; M. Hertzberg; J. Ho; H. C. Hsu; S. Huang; M. Hunault-Berger; B. Inusa; D. Jaulmes; J. Jensen; A. Kattamis; Y. Kilinc; K. H. Kim; S. Kinsey; L. Kjeldsen; A. Koren; M. E. Lai; Y. Lai; J. W. Lee; K. H. Lee; S. H. Lee; L. Legros; C. Li; C. K. Li; Q. Li; K. H. Lin; W. Linkesch; M. Lübbert; D. Lutz; A. J. Mohamed Thalha; G. Mufti; P. Muus; Heinrich Heine Universitat; Alma Mater Studiorum Universita di Bologna; Universita degli Studi di Pavia; Hopital Avicenne; Medizinische Hochschule Hannover (MHH); Hopital Brabois Adultes; Universitatsklinikum Ulm; Mater Hospital; Universite Paris Descartes; Novartis Pharmaceuticals; Novartis International AG; Hopital Saint Vincent-de-Paul GHICL; Istanbul Universitesi; Azienda Policlinico Umberto I; Hospital Universitario Virgen del Rocio; Hopital de Hautepierre; Azienda Ospedaliera Brotzu - Businco; Hospital de Cruzes; Aristotle University of Thessaloniki; Sir Charles Gairdner Hospital; Ege Universitesi; Hospital Universiti Sains Malaysia; Osp. Bologna; Klinikum der Johannes-Gutenberg-Universitat und Fachbereich Medizin; Hopitaux universitaires de Geneve; Hopital Purpan; Amtssygehusetl Herlev; CHU de Limoges; Az. Ospedaliera Universitaria St. Anna; Cliniques Universitaires UCL; CHU Hopitaux de Bordeaux; Monash Medical Centre; Leeds General Infirmary; Institut Jules Bordet; Universita degli Studi di Milano; Ospedale Civico M. Ascoli; Clinique Victor Hugo; Fondazione IRCCS Policlinico San Matteo; Larissa General Hospital; University of Malaya Medical Centre; Mahidol University; Leicester Royal Infirmary; Chiang Mai University; University Hospitalof Thessaloniki AHEPA; Hopital Clemenceau; Ospedale S. Eugenio; Hopital Pontchaillou; KU Leuven– University Hospital Leuven; Ernst-Moritz-Arndt-Universitat Greifswald; Hopital Saint-Louis; Technical University of Munich; University of Athens Medical School; Dresden University Faculty of Medicine and University Hospital Carl Gustav Carus; Ain Shams University; Cairo University; Hillerod Hospital; Centre Hospitalier Universitaire de Liege; Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli; E.O. Ospedali Galliera; Azienda Ospedaliera Brotzu - Microcitemico; Medizinische Universitat Innsbruck; Hopital Henri Mondor; Hadassah University Medical Centre; Royal Melbourne Hospital; Hacettepe Universitesi; Queen Mary Hospital Hong Kong; Universitatsmedizin Gottingen; Gemeinschaftspraxis Brudler/ Heinrich; Westmead Hospital; Royal Prince Alfred Hospital; Veterans General Hospital-Taipei; Guang Zhou Zhong Shan No.2 Hospital; CHU Angers; Evelina Children's Hospital; Hopital Saint-Antoine; Aarhus Amtssygehus, Aarhus University Hospital; University of Athens; Cukurova Universitesi; Samsung Medical Center, Sungkyunkwan University; St James's University Hospital; Rigshospitalet; Emek Medical Center; Hospital of Nanjing Medical University; The Catholic University of Korea; Asan Medical Center; Royal Adelaide Hospital; Centre Hospitalier Universitaire de Nice, Hopital l'Archet; Nanfang Hospital; Prince of Wales Hospital Hong Kong; Branch of Shanghai No.1 Hospital; National Taiwan University Hospital; LKH-Universitatsklinikum Graz; Universitats Klinikum Freiburg und Medizinische Fakultat; A. Ö. Krankenhausder Elisabethinen; Hospital Universiti Kebangsaan Malaysia; King's College Hospital NHS Foundation Trust; Radboud University Nijmegen Medical Centre
2-Aug-2012Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled studyAli T. Taher; John Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Jacqueline Ros; Yiyun Zhang; Dany Habr; Maria Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; Chulalongkorn University; Universita degli Studi di Cagliari; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano
18-Jun-2015Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok; Antonis Kattamis; M. Domenica Cappellini; Amal El-Beshlawy; Raffaella Origa; Mohsen Elalfy; Yurdanur Kilinç; Silverio Perrotta; Zeynep Karakas; Vip Viprakasit; Dany Habr; Niculae Constantinovici; Junwu Shen; John B. Porter; Ege University Medical School; University of Athens; Universita degli Studi di Milano; Cairo University; Universita degli Studi di Cagliari; Ain Shams University; Cukurova Universitesi; Child and of General and Specialist Surgery; Istanbul Tip Fakultesi; Mahidol University; Novartis Pharmaceuticals; Novartis International AG; UCL Cancer Institute
1-Nov-2011Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: A pooled analysisMichael Makanga; Quique Bassat; Catherine O. Falade; Zulfiqarali G. Premji; Srivicha Krudsood; Philip Hunt; Verena Walter; Hans Peter Beck; Anne Claire Marrast; Marc Cousin; Philip J. Rosenthal; European & Developing Countries Clinical Trials Partnership; Universitat de Barcelona; Centro de Investigação em Saúde de Manhiça; University of Ibadan; Muhimbili University of Health and Allied Sciences; Mahidol University; Novartis Horsham Research Centre; Novartis International AG; Universitat Basel; University of California, San Francisco
1-Nov-2006Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: A pooled analysis of individual patient data from randomized clinical trialsEdgar A. Mueller; Michele van Vugt; Wilhelm Kirch; Kim Andriano; Philip Hunt; Patricia Ibarra de Palacios; Dresden University Faculty of Medicine and University Hospital Carl Gustav Carus; Mahidol University; University of Amsterdam; Novartis Pharmaceuticals Corporation; Novartis Horsham Research Centre; Novartis International AG
1-Jun-1999Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malariaM. Van Vugt; P. Wilairatana; B. Gemperli; I. Gathmann; L. Phaipun; A. Brockman; C. Luxemburger; N. J. White; F. Nosten; S. Looareesuwan; Shoklo Malaria Research Unit; Mahidol University; Novartis International AG
22-Apr-2016Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: Results from the 2-year roadmap strategyTeerha Piratvisuth; Piyawat Komolmit; Henry L.Y. Chan; Tawesak Tanwandee; Wattana Sukeepaisarnjaroen; Mário G. Pessoa; Eduardo Fassio; Suzane K. Ono; Fernando Bessone; Jorge Daruich; Stefan Zeuzem; Michael Manns; Alkaz Uddin; Yuhong Dong; Aldo Trylesinski; Prince of Songkla University; Chulalongkorn University; Chinese University of Hong Kong; Mahidol University; Khon Kaen University; Universidade de Sao Paulo - USP; Hospital Nacional Professor Dr. Alejandro Posadas; Universidad Nacional de Rosario; Hospital de Clinicas Jose de San Martin; Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität Frankfurt am Main; Medizinische Hochschule Hannover (MHH); Novartis Pharmaceuticals Corporation; Novartis International AG
1-May-2012Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisisFranck E. Nicolini; Tamas Masszi; Zhixiang Shen; Neil J. Gallagher; Saengsuree Jootar; Bayard L. Powell; Pedro Enrique Dorlhiac-Llacer; Ming Zheng; Tomasz Szczudlo; Anna Turkina; Hopital Edouard Herriot; Szent Laszlo Hospital; Ruijin Hospital; Novartis International AG; Mahidol University; Wake Forest University; Universidade de Sao Paulo - USP; Novartis Pharmaceuticals Corporation; National Research Center for Hematology
1-Jan-2012Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phaseFranck E. Nicolini; Anna Turkina; Zhi Xiang Shen; Neil Gallagher; Saengsuree Jootar; Bayard L. Powell; Carmino De Souza; Ming Zheng; Tomasz Szczudlo; Philipp Le Coutre; Hopital Edouard Herriot; National Research Center for Hematology; Ruijin Hospital; Novartis International AG; Mahidol University; Wake Forest University Baptist Medical Center; Universidade Estadual de Campinas; Novartis Pharmaceuticals Corporation; Charité – Universitätsmedizin Berlin
18-Jan-2013Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasVip Viprakasit; Norbert Gattermann; Jong Wook Lee; John B. Porter; Ali T. Taher; Dany Habr; Nicolas Martin; Gabor Domokos; Maria Domenica Cappellini; Mahidol University; Heinrich Heine Universitat; The Catholic University of Korea; UCL; American University of Beirut; Novartis Pharmaceuticals; Novartis International AG; Universita degli Studi di Milano